This article about reports of pain and fainting linked to Gardasil, the vaccine used to decrease risk of cervical cancer, fails to make the case for its publication.
By emphasizing fleeting pain and an uNPRoven link of fainting, and failing to emphasize the vaccine’s established benefits, the article does not serve the public interest well.
Curiously, the article acknowledges these shortcomings by including expert commentary that calls the story’s premises into question. The reporter and editor clearly knew the article’s thesis is not sustained by data and expert observations.
Why was it published?
The article states that the shots cost $120. The cost is around $120 per injection; three injections are required.
Using only the $120 figure is misleading. Most media reports more accurately cite the total cost of $300 to $400 for the series.
The article does not report the efficacy of the vaccine in preventing cervical cancer, thereby providing no corresponding balance.
The article focuses on harms related to the Gardasil vaccine.
Yet by focusing on one of the more trivial side effects, pain at the injection site, it fails to mention more severe side effects, such as Guillian Barre syndrome. Five percent of reported adverse effects were considered serious. Since 7 million vaccinations have been given, this 5 percent figure of serious events is certainly worth mentioning. Highlighting pain on injection seems a bit trivial in this context.
The articles uses informal observations and lower-quality data to make the case that the injections are unsually painful and linked to fainting.
The article fails to make clear the context and source of the data on fainting. The description in the article suggests the data is from the CDC/FDA Vaccine Adverse Event Reporting System, which accepts voluntary reports from across the healthcare system. The data is considered raw and at best suggestive of patterns worthy of investigation. The article should have made clear the source and limitations of the data.
It is not clear whether the number of reports linked to Gardasil are higher or lower than would be expected with any vaccination given to the same group of people.
The article exaggerates the amount and importance of injection-site pain, and it implies without justification that it is more likely to lead to fainting than other vaccines given to girls and teens.
The article quotes one patient, two clinicians, and one CDC expert in immunization safety. It also draws on raw federal data (without identifying its source) and information from the drug’s maker. Because of the multiple sources used, we’ll rate this satisfactory.
However, a key shortcoming is the failure to provide any detail about the "recent meeting of vaccine experts," where the public health authority comments about pain.
The article fails to make clear that this is the only vaccine shown to reduce the incidence of the types of human papilloma virus which are responsible for a majority of cervical cancers.
Tha story does indicate the vaccine has been available for a year. However, the main point of the story is the level of discomfort associated with the injection and the development of syncope in some recipients. But without discussing how widely the vaccine has been used, case reports provide no useful information. The fact that over 7 million doses of the vaccine has been distributed would have been a valuable piece of information for the readers.
The story does note that Gardasil is an "important new protection" but points out that another version in in clinical trials.
There is no evidence the article is based on a press release.
Systematic, Criteria-Driven
Like claiming that the coronavirus vaccines could leave people “magnetized” https://www.washingtonpost.com/politics/2021/12/06/some-doctors-spreading-coronavirus-misinformation-are-being-punished/
Like Michael Corleone of science reporting that @garyschwitzer is (he tries to get out, bullshit disguised as #science #journalism keeps pulling him back in!), he drops this on @nytimes idiocy 🙄 in reporting T1 diabetes "cure"
HT @HealthNewsRevu
https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like